1. Home
  2. RXRX
  3. RXRX News

Latest Recursion Pharmaceuticals Inc. (RXRX) News on May 9, 2025

Earnings Release: Here's Why Analysts Cut Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target To US$7.43
RXRX

Simply Wall St.

2 days ago

Earnings Release: Here's Why Analysts Cut Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target To US$7.43

Recursion axes drug programmes to streamline pipeline
RXRX

Pharmaceutical Technology

3 days ago

Recursion axes drug programmes to streamline pipeline

RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
RXRX

Zacks

3 days ago

RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates

Recursion to Participate in Upcoming Investor Conferences
RXRX

GlobeNewswire

3 days ago

Recursion to Participate in Upcoming Investor Conferences

RXRX

GuruFocus.com

3 days ago

Recursion Pharmaceuticals Inc (RXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships ...

Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday
RXRX

Motley Fool

4 days ago

Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday

Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial Results
RXRX

Simply Wall St.

4 days ago

Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial Results

AI specialist Recursion trims pipeline in latest shakeup
RXRX

BioPharma Dive

4 days ago

AI specialist Recursion trims pipeline in latest shakeup

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
RXRX

Zacks

4 days ago

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates

RXRX

MT Newswires

4 days ago

Recursion Pharmaceuticals Q1 Loss Widens, Revenue Increases

RXRX

Associated Press Finance

4 days ago

Recursion Pharmaceuticals: Q1 Earnings Snapshot

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
RXRX

GlobeNewswire

4 days ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

RXRX

MT Newswires

4 days ago

Recursion Pharmaceuticals Reports Promising Early Results for Familial Adenomatous Polyposis Drug Trial

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
RXRX

GlobeNewswire

5 days ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)?
RXRX

Insider Monkey

10 days ago

Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)?

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
RXRX

Zacks

11 days ago

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
RXRX

GlobeNewswire

11 days ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?
RXRX

Zacks

14 days ago

Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?

3 Monster Stocks to Hold for the Next 10 Years
RXRX

Motley Fool

16 days ago

3 Monster Stocks to Hold for the Next 10 Years

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
RXRX

GlobeNewswire

17 days ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know
RXRX

Zacks

18 days ago

Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know

Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal
RXRX

Simply Wall St.

21 days ago

Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal

This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?
RXRX

Motley Fool

21 days ago

This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?

RXRX

MT Newswires

23 days ago

Recursion Pharmaceuticals Licenses HealthVerity's Real-World Data

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data
RXRX

PR Newswire

23 days ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?
RXRX

Insider Monkey

24 days ago

Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?

Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA”
RXRX

Insider Monkey

25 days ago

Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA”

Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?
RXRX

Zacks

25 days ago

Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?

Why Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week?
RXRX

Insider Monkey

a month ago

Why Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week?

Why Recursion Pharmaceuticals, Inc. (RXRX) Surged On Friday?
RXRX

Insider Monkey

a month ago

Why Recursion Pharmaceuticals, Inc. (RXRX) Surged On Friday?

Recursion Pharma rises, Intel & Five Below fall: Trending Tickers
RXRX

Yahoo Finance Video

a month ago

Recursion Pharma rises, Intel & Five Below fall: Trending Tickers

Why Recursion Pharmaceuticals Stock Is Skyrocketing Today
RXRX

Motley Fool

a month ago

Why Recursion Pharmaceuticals Stock Is Skyrocketing Today

RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
RXRX

Zacks

a month ago

RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
RXRX

GlobeNewswire

a month ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

RXRX

MT Newswires

a month ago

Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
RXRX

GlobeNewswire

a month ago

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Recursion Pharmaceuticals (NasdaqGS:RXRX) Sees 27% Weekly Drop After Leadership Changes
RXRX

Simply Wall St.

a month ago

Recursion Pharmaceuticals (NasdaqGS:RXRX) Sees 27% Weekly Drop After Leadership Changes

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
RXRX

Motley Fool

a month ago

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March

Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market
RXRX

Fortune

a month ago

Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market

Recursion to Participate in Upcoming Investor Conference
RXRX

GlobeNewswire

a month ago

Recursion to Participate in Upcoming Investor Conference

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
RXRX

Motley Fool

a month ago

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today

Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
RXRX

Motley Fool

a month ago

Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?

Is Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit?
RXRX

Insider Monkey

a month ago

Is Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit?

Why Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday?
RXRX

Insider Monkey

a month ago

Why Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday?

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
RXRX

Zacks

2 months ago

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today

Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering
RXRX

Simply Wall St.

2 months ago

Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering

Why Recursion Pharmaceuticals (RXRX) Went Up on Monday?
RXRX

Insider Monkey

2 months ago

Why Recursion Pharmaceuticals (RXRX) Went Up on Monday?

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
RXRX

GlobeNewswire

2 months ago

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

Big tech meets biotech: Recursion and the AI gold rush in pharma
RXRX

Pharmaceutical Technology

2 months ago

Big tech meets biotech: Recursion and the AI gold rush in pharma

Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’
RXRX

Insider Monkey

2 months ago

Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’

Why Recursion Pharmaceuticals Stock Is Sinking Today
RXRX

Motley Fool

2 months ago

Why Recursion Pharmaceuticals Stock Is Sinking Today

Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?
RXRX

Motley Fool

2 months ago

Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?

4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today
RXRX

Motley Fool

2 months ago

4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today

This Biotech Stock Could Be the Best Investment of the Decade
RXRX

Motley Fool

2 months ago

This Biotech Stock Could Be the Best Investment of the Decade

Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?
RXRX

Motley Fool

2 months ago

Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?

News Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts
RXRX

Simply Wall St.

2 months ago

News Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts

Why Recursion Pharmaceuticals, Inc. (RXRX) Crashed on Monday
RXRX

Insider Monkey

2 months ago

Why Recursion Pharmaceuticals, Inc. (RXRX) Crashed on Monday

RXRX

GuruFocus.com

2 months ago

Recursion Pharmaceuticals Inc (RXRX) Q4 2024 Earnings Call Highlights: Strong Financial ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) Surges 6% Following US$500 Million Follow-On Equity Offering
RXRX

Simply Wall St.

2 months ago

Recursion Pharmaceuticals (NasdaqGS:RXRX) Surges 6% Following US$500 Million Follow-On Equity Offering

Company News for Mar 3, 2025
RXRX

Zacks

2 months ago

Company News for Mar 3, 2025

Recursion Pharmaceuticals Full Year 2024 Earnings: Misses Expectations
RXRX

Simply Wall St.

2 months ago

Recursion Pharmaceuticals Full Year 2024 Earnings: Misses Expectations

RXRX

MT Newswires

2 months ago

Sector Update: Health Care Stocks Steady Pre-Bell Friday

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
RXRX

Zacks

2 months ago

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates

RXRX

MT Newswires

2 months ago

Recursion Pharmaceuticals Q4 Loss Widens, Revenue Declines

RXRX

Associated Press Finance

2 months ago

Recursion Pharmaceuticals: Q4 Earnings Snapshot

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
RXRX

GlobeNewswire

2 months ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration
RXRX

Pharma Voice

2 months ago

AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
RXRX

GlobeNewswire

3 months ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025?
RXRX

Insider Monkey

3 months ago

Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025?

Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX)
RXRX

Insider Monkey

3 months ago

Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX)

Why Recursion Pharmaceuticals, Inc. (RXRX) is the Best Performing Healthcare Stock So Far in 2025
RXRX

Insider Monkey

3 months ago

Why Recursion Pharmaceuticals, Inc. (RXRX) is the Best Performing Healthcare Stock So Far in 2025

Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
RXRX

GlobeNewswire

3 months ago

Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City

Recursion CEO launches pre-seed fund in response to NIH cuts
RXRX

BioPharma Dive

3 months ago

Recursion CEO launches pre-seed fund in response to NIH cuts

Recursion Pharmaceuticals Stock Scores RS Ratings Over 90
RXRX

Investor's Business Daily

3 months ago

Recursion Pharmaceuticals Stock Scores RS Ratings Over 90

Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX)
RXRX

Insider Monkey

3 months ago

Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX)

Altitude Lab Startups Raise $154M in Capital
RXRX

GlobeNewswire

3 months ago

Altitude Lab Startups Raise $154M in Capital

Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock
RXRX

Zacks

3 months ago

Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock

Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week
RXRX

Insider Monkey

3 months ago

Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week

Why Recursion Pharmaceuticals Inc. (RXRX) Soared on Friday?
RXRX

Insider Monkey

3 months ago

Why Recursion Pharmaceuticals Inc. (RXRX) Soared on Friday?

Why Recursion Pharmaceuticals Stock Is Soaring Today
RXRX

Motley Fool

3 months ago

Why Recursion Pharmaceuticals Stock Is Soaring Today

Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
RXRX

Zacks

3 months ago

Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why

Why Recursion Pharmaceuticals Inc. (RXRX) Surged On Wednesday
RXRX

Insider Monkey

3 months ago

Why Recursion Pharmaceuticals Inc. (RXRX) Surged On Wednesday

Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?
RXRX

Zacks

3 months ago

Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
RXRX

Zacks

3 months ago

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Why Recursion Pharmaceuticals (RXRX) Stock Went Down On Thursday?
RXRX

Insider Monkey

3 months ago

Why Recursion Pharmaceuticals (RXRX) Stock Went Down On Thursday?

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
RXRX

GlobeNewswire

3 months ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
RXRX

Zacks

3 months ago

Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note

Institutional owners may consider drastic measures as Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) recent US$130m drop adds to long-term losses
RXRX

Simply Wall St.

3 months ago

Institutional owners may consider drastic measures as Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) recent US$130m drop adds to long-term losses

Is Recursion Pharmaceuticals (RXRX) the Cheap AI Stock to Buy in 2025?
RXRX

Insider Monkey

3 months ago

Is Recursion Pharmaceuticals (RXRX) the Cheap AI Stock to Buy in 2025?

Recursion Pharmaceuticals (RXRX): Industrializing Drug Discovery with AI Amid J.P. Morgan’s ‘Neutral’ Outlook
RXRX

Insider Monkey

3 months ago

Recursion Pharmaceuticals (RXRX): Industrializing Drug Discovery with AI Amid J.P. Morgan’s ‘Neutral’ Outlook

Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?
RXRX

Zacks

4 months ago

Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?

Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday
RXRX

Insider Monkey

4 months ago

Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
RXRX

Motley Fool

4 months ago

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth
RXRX

Insider Monkey

4 months ago

Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth

Is Recursion Pharmaceuticals Stock a Buy?
RXRX

Motley Fool

4 months ago

Is Recursion Pharmaceuticals Stock a Buy?

Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing
RXRX

Zacks

4 months ago

Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing

RXRX

MT Newswires

4 months ago

Recursion Pharmaceuticals Insider Sold Shares Worth $287,200, According to a Recent SEC Filing

Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?
RXRX

Zacks

4 months ago

Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?

RXRX

MT Newswires

4 months ago

KeyBanc Lowers Price Target on Recursion Pharmaceuticals to $10 From $12, Keeps Overweight Rating

Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA
RXRX

TipRanks

4 months ago

Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA

Share on Social Networks: